In breast cancer, the Grp94 N62Q mutant, which fails to undergo glycosylation, exhibits reduced epichaperome formation, diminished plasma membrane localization, and attenuated EGFR signaling compared to N217A mutant, which retain EGFR signaling. This evidence concerns the gene EGFR and breast cancer.